Those prospective parturients that express that they may want an epidural labour analgesia for their delivery will be informed about the possibility to choose between a pump driven epidural or midwife administered intermittent boluses.

Start Date01 Dec 2024

Sponsor / Collaborator

Womens Hospital Indianapolis LP

[+1]

NCT06051227 / RecruitingPhase 3IIT

Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) Trial

Fentanyl and esketamine are both standard of care for treatment of acute severe traumatic pain in the prehospital setting in the Netherlands. However, it is not known whether they are equally effective and safe. It is also not known whether intranasal (IN) administration of fentanyl or esketamine is equally effective and safe as intravenous (IV) administration.
The FORE-PAIN trial is a double-blind multi-arm randomized non-inferiority trial comparing Fentanyl IN, esketamine IV and esketamine IN (intervention arms) to fentanyl IV (comparator arm) for prehospital management of traumatic pain. The investigators hypothesize that all intervention arms provide analgesia that is non-inferior to the comparator arm, and that all study arms are equally safe.

Start Date11 Jan 2024

Sponsor / Collaborator

Ambulance Inc. of Laurel County

NCT06017141 / RecruitingPhase 2IIT

VIVA: Volatile or IV Anesthesia for Cancer

This trial evaluates how inhalational anesthesia (drawn in through the lungs) and total intravenous anesthesia (TIVA) (through a needle in a vein in the arm) change the body's ability to recover from surgery or whether they impact the immune system immediately after surgery in patients with colon cancer. It is unknown whether these types of anesthesia change recovery from surgery or change the chances cancer comes back following surgery. This study may help researchers learn how different types of anesthesia affect recovery from colon cancer surgery.

Start Date22 May 2023

Sponsor / Collaborator

University of Kansas

[+1]

100 Clinical Results associated with Fentanyl Citrate

100 Translational Medicine associated with Fentanyl Citrate

100 Patents (Medical) associated with Fentanyl Citrate

564

Literatures (Medical) associated with Fentanyl Citrate

01 Jan 2024·Reproduction in domestic animals = Zuchthygiene

Evaluation of pharmacological alternatives to reduce the pain and discomfort produced by electroejaculation in rams

Article

Author: Crespilho, André Maciel ; de Almeida Gélio, Leonardo ; Nichi, Marcílio ; Oba, Eunice ; Green, Renata Elisa ; da Silva, Mariana Karla Francolino ; de Freitas, Douglas Anderson

Abstract:

Electroejaculation (EE) represents the main technique for semen collection from domestic and wild animals independently of libido. However, the technique is associated with intense involuntary muscle contractions, vocalization, ataxia and lying down, caused by the electric stimulation of the nerves in the caudal epigastric region. These clinical manifestations represent important indicators of discomfort. In this context, the objective of this study was to evaluate two protocols of local anaesthetic blockade and two anatomical access for pharmacological desensitization of the caudal epigastric innervation as alternatives to promote comfort and reduce stress associated with EE in rams. For the study, four clinically healthy Dorper rams were selected. All animals were subjected to a design consisting of five semen collection treatments (n = 3 collections per treatment): T1—control, conventional EE without local anaesthetic blockade; T2, EE with ventral blockade (VB) of epigastric innervation using lidocaine hydrochloride 2%; T3, EE with VB of epigastric innervation using a combination of lidocaine hydrochloride 2% and fentanyl citrate; T4, EE with blockade of epigastric innervation through the perineal access using lidocaine hydrochloride 2%; T5, EE with blockade of epigastric innervation through the perineal access using a combination of lidocaine hydrochloride and fentanyl citrate. Seminal samples resulting from EE were subjectively evaluated for sperm motility and concentration, vigour and volume. Additionally, blood serum samples were collected for quantification of cortisol and creatine kinase (CK) enzyme. Assessments of stress and discomfort were conducted by measuring blood pressure, heart rate (HR) and respiratory rate (RR), as well as observing involuntary muscle contractions, ataxia and animal vocalization. No variations in blood pressure, sperm motility, vigour, CK, and cortisol were observed among the treatments. Individual variations were observed for the occurrence of vocalization (p = .0066), but there were no differences between the groups. Anaesthetic blockades conducted using the combination of lidocaine and fentanyl resulted in a lower incidence of ataxia during EE (p < .0001). It is concluded that the combination of fentanyl citrate and lidocaine hydrochloride results in less discomfort for animals undergoing EE, regardless of the anatomical access used for local anaesthetic blockades.

01 Dec 2023·Heliyon

Clinical and pharmacokinetics overview of intranasal administration of fentanyl

Review

Author: Saeedi, Farhad ; Nakhaee, Samaneh ; Mehrpour, Omid

Due to the presence of large surfaces and high blood supply, drug delivery through the nasal route of administration is the appropriate route to administrate drugs with rapid onsets of action. Bypassing first-pass metabolism can increase drug bioavailability. The physicochemical properties of fentanyl led to a need to develop formulations for delivery by multiple routes. Several approved inter-nasal fentanyl products in Europe and the USA have been used in prehospital and emergency departments to treat chronic cancer pain and used to treat severe acute abdominal and flank pain. Analgesia durations and onsets were not significantly different between intranasal and intravenous fentanyl in patients with cancer breakthrough pain and were well-tolerated in the long term. Intranasal Fentanyl (INF) at a 50 μg/ml concentration decreased renal colic pain to the lowest level in 30 min. Possible adverse effects specific to INF are epistaxis, nasal wall ulcer, rhinorrhea, throat irritation, dysgeusia, nausea, and vomiting. However, there is limited available literature about the serious adverse effects of INF in adults and children. Intranasal Fentanyl Spray (INFS) results in significantly higher plasma concentrations and has a lower T_max than oral transmucosal formulation, and the bioavailability of fentanyl in intranasal formulations is very high (89 %), particularly in pectin-containing formulations such as PecFent and Lazanda.

22 Jul 2023·BMC anesthesiology

Effect of nalbuphine plus ropivacaine on vaginal labor in epidural analgesia.

Article

Author: Cao, Xiao-Sheng ; Pang, Zhao ; Wen, Xue-Jin ; Ou, Lian-Chun ; Yin, Biao ; Liu, Li-Wen ; Liu, Guo-Hua ; He, Quan-Yan

BACKGROUND:

Various approaches using epidural analgesia have been employed for relieving labor pain and promoting spontaneous delivery. We aimed to evaluate the effect of nalbuphine and ropivacaine versus fentanyl and ropivacaine on the duration of delivery in parturients.

METHODS:

Clinical data of 160 full-term primiparous women who received either nalbuphine or fentanyl in combination with ropivacaine infusion for epidural labor analgesia in our hospital from December 2020 to May 2022 were retrospectively analyzed. The participants were divided into two groups based on anesthesia methods: nalbuphine group (NR group, n = 78) received 0.2 mg/mL nalbuphine combined with 0.1% ropivacaine hydrochloride for patient-controlled epidural analgesia (PCEA) and fentanyl group (FR group, n = 82) received 2 ug/mL fentanyl citrate and 0.1% ropivacaine hydrochloride for PCEA. Both groups received an epidural blockade for labor analgesia at lumbar 2-3 interspace. The duration of the first, second, and third stages of labor, the onset of analgesia, and time before delivery (T0), 15 min of analgesia (T1), 30 min of analgesia (T2), full opening of the uterine opening (T3),exerts force during childbirth(T4), heart rate (HR), blood pressure (BP), blood saturation (SpO2), visual analogue pain scale (VAS) score, Ramsay sedation score, and modified Bromage score, and 5 min were recorded at 2 h postpartum (T5). The neonatal Apgar score, neonatal behavioral neurological assessment (NBNA) score, maternal nausea, vomiting, and itchy skin were recorded.

RESULTS:

Compared with the FR group, the first stage of labor duration (p < 0.05) and total duration of labor (p < 0.05) were shortened and the onset of analgesia (p < 0.05) was increased in the NR group. NR group had lower incidence of urinary retention than FR group (p < 0.05). The maternal and neonatal investigational parameters and scores had no significant difference between the two groups.

CONCLUSIONS:

Nalbuphine combined with ropivacaine in epidural block labor has a faster onset of analgesia and has a lower incidence of urinary retention than fentanyl combined with ropivacaine, and nalbuphine shortens the duration of the first and total stages of labor. Both nalbuphine and fentanyl can reduce pain during labor, have little effect on maternal hemodynamics, and have no significant effect on neonatal Apgar or NBNA scores.

News (Medical) associated with Fentanyl Citrate

13 Dec 2023

·www.globenewswire.com

TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. “I am pleased to welcome Thomas King to our Board of Directors,” said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. “Tom is an exceptionally accomplished executive who has held leadership positions at life sciences companies over the last three decades. In addition, his extensive board experience will provide us with valuable insights and perspectives as we seek to advance our two lead candidates, TFF VORI and TFF TAC, into later-stage clinical testing.” “I am very excited to join the Board of TFF Pharmaceuticals at a time when the Company is demonstrating how its ground-breaking Thin Film Freezing technology can be applied in the clinic to address the significant unmet need in patients with rare diseases,” said Mr. King. “I look forward to working alongside Harlan and our fellow Board members to help advance the company’s mission of significantly improving new and existing therapies for the benefit of patients.” Mr. King has over 30 years of executive leadership and board experience in the life sciences industry. Presently, Mr. King sits on the board of several companies, including Achieve Life Sciences (Nasdaq: ACHV), Kinaset Therapeutics, and Concentric Analgesics. From 2003 to 2016, Mr. King served as the President, Chief Executive Officer and Director of Alexza Pharmaceuticals, where he led multiple stock offerings and debt transactions from 2003 through 2015 (IPO in 2006), raising in excess of $600mm and ultimately leading to the successful M&A transaction with Grupo Ferrer. Prior to joining Alexza, he was the President, Chief Executive Officer and Director of Cognetix, Inc. From 1994 to 2000, Mr. King served in multiple executive roles and as a Director with Anesta Corp., where he led two successful follow-on stock offerings, NDA and MAA approvals for oral transmucosal fentanyl citrate (Actiq®), and a successful M&A transaction with Cephalon in 2000. Earlier in his career, Mr. King served as Vice President of Marketing and Business Development with Somatogen, Inc., and before joining Somatogen, he served as Director of the Cardiovascular Business Unit at Abbott Laboratories, Pharma Products Division. Mr. King received his B.A. degree in chemistry from McPherson College and an MBA from the University of Kansas Graduate School of Business. ABOUT TFF PHARMACEUTICALS’ THIN FILM FREEZING (TFF) TECHNOLOGY TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The TFF process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by TFF can deliver as much as 75% of the dose to the deep lung. TFF does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of TFF can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products. ABOUT TFF PHARMACEUTICALS TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company’s versatile TFF technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF VORI (Voriconazole Inhalation Powder) and TFF TAC (Tacrolimus Inhalation Powder). The Company continues collaborations with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by over 170 patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com. SAFE HARBOR This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including, plans for releasing initial clinical data by the end of 2023 and the benefits of the Company’s TFF platform. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to release initial clinical data for TFF VORI and TFF TAC by the end of 2023 or, if it is able to do so, that such clinical data will be positive, (ii) the risk that the Company’s preclinical and IND enabling studies of the dry powder formulation of the universal influenza vaccine may not be successful, (iii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iv) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, and (iv) those other risks disclosed in the section “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q filed with the SEC on November 14, 2023. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. Investor Relations Contact:Corey Davis, Ph.D. LifeSci Advisors (212) 915-2577cdavis@lifesciadvisors.com Source: TFF Pharmaceuticals, Inc.

Executive ChangeVaccineIPO

17 Jan 2023

·www.biospace.com

Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer

GRAND RAPIDS, Mich.--(BUSINESS WIRE)-- Corium Pharma Solutions, Inc. (“Corium Pharma Solutions” or “CPSI”), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal modalities, today announced the appointment of Dr. Mark Sirgo as Chief Executive Officer and member of the Board of Directors. Dr. Sirgo is a pharmaceutical executive with over 35 years’ experience in the industry, including founding and serving as the President, Chief Executive Officer, and Vice Chairman of BioDelivery Sciences International, Inc. (“BDSI”), a commercial-stage specialty pharmaceutical company focused on pain and addiction management. During his tenure at BDSI, Mark was responsible for creating and overseeing the implementation of the company’s corporate strategy and overseeing all business operations. Additionally, Mark executed on the development, NDA approval, and commercialization of three products in neurological and pain indications, Onsolis®, Bunavail®, and Belbuca®. BDSI was successfully sold to Collegium Pharmaceutical, Inc. in March 2022. Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike. CPSI currently manufactures a variety of over the counter and prescription products, including Proctor & Gamble Co’s (NYSE: PG) entire Crest Whitestrips franchise, Agile Therapeutics, Inc.’s (NASDAQ: AGRX) Twirla®, and Corium, LLC’s (“Corium”) ADLARITY®, a once-weekly, transdermal donepezil patch indicated for the treatment of mild, moderate, and severe dementia in Alzheimer’s patients. Mark joins Corium Pharma Solutions shortly after its formation in October 2022, when Webster Equity Partners (“Webster”) acquired the standalone business unit from its former, commercial-stage biopharmaceutical parent company, Corium. Corium’s original investor, Gurnet Point Capital (“Gurnet Point”), remains as a joint owner in Corium Pharma Solutions and each Gurnet Point and Webster have equal board representation. “I am thrilled to welcome Mark as Chief Executive Officer of Corium Pharma Solutions,” said Travis Wilson, Partner at Gurnet Point. “Mark’s decades of industry experience and proven track record of research, development, and commercialization of pharmaceutical products make him the ideal leader for the next phase of Corium Pharma Solutions’ growth. He is uniquely qualified to step into the leadership role and Corium Pharma Solutions will benefit from his deep product development, regulatory, and commercial experience across numerous therapeutics areas.” “I am excited to have the opportunity to lead the Corium Pharma Solutions team as we continue to build on the company’s historical successes and further establish its leadership position in transdermal contract development and manufacturing,” said Dr. Mark Sirgo, Chief Executive Officer. “With the backing and financial support of Gurnet Point and Webster, I look forward to focusing on both supporting our current partners and procuring new business opportunities within our current capabilities, while selectively adding to our breadth of specialty offerings through M&A to extend our commercial product footprint.” Prior to founding BDSI, Mark was Senior Vice President, Global Business Development at PPD, Inc., where he managed global sales and marketing for one of the world’s largest contract research organizations serving biopharmaceutical, pharmaceutical, and device industries. Further, he held several leadership positions at GSK plc in clinical development and marketing and was a Director at Salix Pharmaceuticals, Ltd. prior to its sale to Valeant Pharmaceuticals International, Inc. in 2015. Mark also currently serves as Chairman of 9 Meters Biopharma, Inc. (NASDAQ: NMTR) and Genenta Science SpA (NASDAQ: GNTA). Dr. Sirgo holds a PharmD from Philadelphia College of Pharmacy and Sciences, and a BS in Pharmacy from The Ohio State University. About Corium Pharma Solutions Headquartered in Grand Rapids, Michigan, Corium Pharma Solutions is a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies. With a track record spanning nearly 30 years, Corium Pharma Solutions offers end-to-end solutions to its partners, from formulation and product development work, through commercial-scale manufacturing and packaging. The company’s success is enabled by its state-of-the-art facilities, highly tenured operational leadership, and proprietary drug delivery technologies, CORPLEX™ and MICROCOR®. Corium Pharma Solutions is jointly owned by Gurnet Point Capital and Webster Equity Partners. About Gurnet Point Capital Gurnet Point Capital is a leading healthcare fund that invests in de-risked life sciences companies. Gurnet Point primarily focuses on businesses that have high growth potential in the late product development and commercialization stages of their evolution. These companies become partners not just because of their capacity to generate economic value, but also because of their potential to deliver social impact. Gurnet Point’s team of highly experienced industry executives works closely with its portfolio companies, with an active approach driving operational transformation and outsized returns. About Webster Equity Partners Founded in 2003, Webster is a private equity firm that focuses on high impact growth strategies that seek to deliver optimal outcomes for our investors, portfolio companies and the communities that we serve. Our mission is to deliver superior returns to our partners through the investment in and development of purpose driven patient-centric healthcare organizations dedicated to providing best of class clinical care and service to their patients.

Executive ChangeAcquisition

24 Nov 2022

·www.businesswire.com

Grünenthal and Kyowa Kirin International Announce Joint Venture Collaboration for Established Medicines Portfolio

AACHEN, Germany & TOKYO--( BUSINESS WIRE )--Kyowa Kirin Co., Ltd., (TSE:4151, President and CEO: Masashi Miyamoto, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and Grünenthal GmbH (CEO: Gabriel Baertschi), a global, science-based, privately-owned pharmaceutical company, are today announcing they have signed a Joint Venture Collaboration for Kyowa Kirin International's established medicines portfolio. The Joint Venture Collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral® and PecFent® for breakthrough cancer pain, Moventig® for opioid-induced constipation, and Adcal-D3® for osteoporosis. The Joint Venture Collaboration is subject to obtaining customary approvals and clearances, including anti-trust and works councils as legally required. Completion of the deal is anticipated for Q2 2023. The total revenues of the portfolio in 2021 were approximately €200 million. The products are marketed through affiliates in seven major European countries and through a network of partners in various additional territories worldwide. Grünenthal has agreed to pay approximately €80 million upfront plus royalties over the term of the collaboration. Grünenthal will make an additional payment upon purchase of the remaining share and the intellectual property (IP) of the portfolio. “ As a leader in pain management, and with our proven track record in growing established brands, we believe we can help even more patients benefit from this unique group of medicines”, said Gabriel Baertschi, Chief Executive Officer, Grünenthal. “ This portfolio of established brands matches very well with Grünenthal’s geographical footprint and therapeutic areas.” Abdul Mullick, President of Kyowa Kirin International said, “ Our search for a partner included three key priorities: a team who shares our commitment to patients and to our employees, a partner who is looking to support our growth agenda, and a company with which we can establish a close, collaborative partnership that promises benefits for all our stakeholders while operating at the highest ethical standards. This collaboration will bring a renewed focus, the resources and the commercial infrastructure required to grow the established medicines portfolio to deliver life-changing value to more patients.” Subject to approval, Grünenthal will own a 51 percent majority share in the new company. Kyowa Kirin will own a 49 percent share and will initially retain the IP related to the portfolio. Grünenthal intends to purchase the remaining 49 percent share and the IP at the beginning of 2026. About the portfolio The portfolio includes medicines that deliver life-changing value for hundreds of thousands of patients. The portfolio is available in seven major European markets through affiliates and in various additional territories worldwide through a network of partners. Key products in the portfolio include Abstral® and PecFent® (Fentanyl) for breakthrough cancer pain, Moventig® (Naloxegol) for opioid-induced constipation and Adcal-D3® (calcium and vitamin D3) for osteoporosis. About Kyowa Kirin Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based global specialty pharmaceutical company with a more than 70-year heritage, we apply cutting-edge science, including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork, innovation, and integrity. You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com/ . Kyowa Kirin International is a subsidiary of Kyowa Kirin Co., Ltd. About Grünenthal Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain. Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.

License out/in

100 Deals associated with Fentanyl Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D01399	Fentanyl Citrate	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	US	Adalvo Ltd.	16 Jul 2009
Breakthrough Pain	EU	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	IS	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	LI	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	NO	Teva Pharmaceuticals Europe BV	04 Apr 2008
Cancer Pain	US	Cephalon, Inc.	04 Nov 1998
Hyperemesis Gravidarum	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Anesthesia	US	Rising Pharmaceuticals, Inc.Startup	19 Feb 1968

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 3	IT	L. Molteni & C. dei F.lli Alitti Società di Esercizio SpA	01 Sep 2014
Low Back Pain	Phase 3	US	Cephalon, Inc.	01 Sep 2005
Neuralgia	Phase 3	US	Cephalon, Inc.	01 Sep 2005
Neoplasms	Phase 3	US	Cephalon, Inc.	01 Apr 2004
Anemia, Sickle Cell	Phase 2	US	Cephalon, Inc.	01 Oct 2006
Anemia, Sickle Cell	Phase 2	CA	Cephalon, Inc.	01 Oct 2006
Anemia, Sickle Cell	Phase 2	PR	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	US	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	CA	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	PR	Cephalon, Inc.	01 Oct 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02862912 (CTgov)	Phase 4	Drug-Related Side Effects and Adverse Reactions \| Uterine Cervical Incompetence	43	Fentanyl+Chloroprocaine (Chloroprocaine (CP))	noapwecgtg(wfcpuxrosa) = xuajrurwpc fcafyqeuzf (mwixvmhmhz, lyvwododyv - qukbxhaxjr) View more	-	26 May 2020
				Fentanyl+Saline+Bupivacaine (Bupivacaine (BUP))	noapwecgtg(wfcpuxrosa) = djviyjyccr fcafyqeuzf (mwixvmhmhz, pxftiecqzz - gtubscmjwn) View more
NCT02531971 (CTgov)	Phase 4	-	24	Duragesic (Duragesic)	gkcyaianmk(zopwdtwgyk) = iqhfvocwcm yrcwudbrhn (mjkoxdcvhr, orkkmhxfym - heozaecoqy)	-	26 Mar 2020
				fentanyl (Mylan)	gkcyaianmk(zopwdtwgyk) = osletdkqlb yrcwudbrhn (mjkoxdcvhr, xqaawupmtj - fuuvqlrvzj)
NCT01516684 (CTgov)	Phase 2	Neoplasms	33	EMLA cream (Arm A (EMLA))	sbsnibwqdu(zoglsqqqjd) = denuefirts juffecdwfk (ykhimugjpk, vpfuqjvsce - snshacqzxb) View more	-	06 Sep 2019
				Placebo (Arm B (Placebo))	sbsnibwqdu(zoglsqqqjd) = patohgcdfm juffecdwfk (ykhimugjpk, gontlvyeol - zlojvqyojr) View more
NCT03071744 (CTgov)	Phase 2	Neoplasms \| Bone metastases	6	Lazanda	obsovuebgd(ixvurcbeln) = doqewanhwl mpejucglzi (dwgfjjzpyh, kxjpxwozfr - mwgmafemwk) View more	-	23 Jul 2019
NCT00696137 (CTgov)	Phase 3	Cancer Pain \| Respiratory Insufficiency	5	BEMA Fentanyl	ougsvgyazb(ecfhvhatbv) = dxwpzjqoev xpduwursdo (ofjcgytmbl, hyekvkwque - uqrvwbpfrf) View more	-	19 Dec 2018
NCT01158820 (CTgov)	Phase 4	Cough \| Sedation \| Respiratory Insufficiency	50	Fentanyl load+Midazolam load+Benadryl demand (Placebo)	gdiemajtvz(fbyhrmktmy) = hrdlmxtuce wdfqdfiasg (cuyrecevqb, viwzcbpkyp - ioediqkljl) View more	-	31 Oct 2018
				Dexmedetomidine load+Fentanyl demand+Midazolam demand+Benadryl demand+Ketamine maintenance (Dexmedetomidine and Ketamine)	gdiemajtvz(fbyhrmktmy) = lqbgedmgnb wdfqdfiasg (cuyrecevqb, rbvgqejhyg - hpkdtdtblf) View more
NCT03105518 (CTgov)	Phase 4	Pain, Postoperative	100	Acetaminophen+Fentanyl+Oxycodone	ukxkadmqic(lllybvqklh) = gqzbvagrgx lxcblulmnq (cgntdrsouz, tgdljtazml - alhsvpnosg) View more	-	05 Dec 2017
NCT00685295 (CTgov)	Phase 1/2	Pain \| Fractures, Avulsion	60	fentanyl (Arm 1 / Fentora)	ritmrphkhd(ffacvgenln) = vlxbythrer lstcgmmotq (mmxiwaymgd, ltkrejsegn - wghigrzfna) View more	-	09 Feb 2017
				Lansoprazole+Oxycodone (Arm 2 / Percocet/Prevacid)	ritmrphkhd(ffacvgenln) = qxokhfsikl lstcgmmotq (mmxiwaymgd, vxjnuhdfxj - ksumgyqmza) View more
NCT02571634 (CTgov)	Phase 4	Pain, Procedural	23	Lazanda	ddhdnoastr(ktptbthwpm) = nxdpzoydim taztbwwhzk (eorspbuabt, vxjvhgivng - fxvohiotbw) View more	-	25 Oct 2016
NCT01482091 (CTgov)	Phase 4	Vaso-occlusive crisis \| Pain \| Anemia, Sickle Cell	124	Normal saline (Intranasal Saline)	xihtjbwnqj(lbdxwrsqdk) = lizyjzwlrv ayqsszjtoi (qviiuaohon, kttzpymnkl - mmlkazfdlt) View more	-	19 Aug 2016
				Fentanyl Citrate (Intranasal Fentnayl)	xihtjbwnqj(lbdxwrsqdk) = mshnzclifc ayqsszjtoi (qviiuaohon, pvncysscwq - hdksubvuga) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis